门脉性肺动脉高压的诊断与治疗进展

doi:10.3969/j.issn.1672-5069.2014.02.029

实用肝脏病杂志 ›› 2014, Vol. 17 ›› Issue (2): 214-217.doi: 10.3969/j.issn.1672-5069.2014.02.029

门脉性肺动脉高压的诊断与治疗进展

蔡均均综述，韩涛审校

300170 天津市天津医科大学三中心临床学院/天津市第三中心医院肝内科/天津市人工细胞重点实验室/天津市肝胆疾病研究所

收稿日期:2013-08-15 出版日期:2014-08-20 发布日期:2016-04-15
通讯作者: 韩涛 E-mail:hantaomd@126.com
作者简介:蔡均均，女，25岁，硕士研究生。主要从事肝脏疾病研究。E-mail: caijunjungo@163.com
基金资助:
天津市科委基金项目（12JCYBJC17300）

Progress in diagnosis and treatment of patients with portopulmonary hypertension

Cai Junjun，Han Tao.

Department of Hepatology，Tianjin Institute of Hepatobiliary Disease，Third Central Clinical College,Tianjin Medical University，Tianjin 300170，China

Received:2013-08-15 Online:2014-08-20 Published:2016-04-15

摘要/Abstract

摘要： 门脉性肺动脉高压是伴或不伴晚期肝病患者在门静脉高压基础上出现以肺动脉压升高和肺血管阻力增加为特点的疾病。门脉性肺动脉高压显著增加患者病死率。目前尚无明确有效的治疗药物，肝移植是唯一有效的治疗手段。本文重点介绍了门脉性肺动脉高压的流行病学、发病机制、临床表现、诊断、治疗及预后情况。

关键词: 门脉性肺动脉高压, 肝硬化, 诊断, 治疗

Abstract: Portopulmonary hypertension （PPHTN） is defined as the development of pulmonary arterial hypertension associated with increased pulmonary vascular resistance complicating portal hypertension, with or without advanced liver disease. The presence of PPHTN markedly increases mortality. No effective medical therapies are currently available and liver transplantation is the only accepted treatment at the time. This review stresses on the epidemiology, pathophysiology, clinical presentation, diagnosis, treatment and the prognosis of PPHTN.

Key words: Portopulmonary hypertension, Liver cirrhosis, Diagnosis, Treatment

蔡均均综述，韩涛审校. 门脉性肺动脉高压的诊断与治疗进展[J]. 实用肝脏病杂志, 2014, 17(2): 214-217.

Cai Junjun，Han Tao.. Progress in diagnosis and treatment of patients with portopulmonary hypertension[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2014, 17(2): 214-217.

参考文献

[1] Porres-Aguilar M，Altamirano JT，Torre-Delgadillo A，et al. Portopulmonary hypertension and hepatopulmonary syndrome:a clinician-oriented overview. Eur Respir Rev，2012，21（125）:223-233.
[2] Swanson KL，Wiesner RH，Nyberg SL，et al. Survival in portopulmonary hypertension:Mayo clinic experience categorized by treatment subgroups. Am J Transplant，2008，8（11）:2445-2453.
[3] McDonnell PJ，Toye PA，Hutchins GM，et al. Primary pulmonary hypertension and cirrhosis:are they related Am Rev Respir Dis，1983，127（4）:437-441.
[4] Tsiakalos A，Hatzis G，Moyssakis I，et al. Portopulmonary hypertension and serum endothelin levels in hospitalized patients with cirrhosis. Hepatobiliary Pancreat Dis Int，2011，10（4）:393-398.
[5] Chen HS，Xing SR，Xu WG，et al. Portopulmonary hypertension in cirrhotic patients:Prevalence，clinical features and risk factors. Exp Ther Med，2013，5（3）:819-824.
[6] Kawut SM，Krowka MJ，Trotter JF，et al. Clinical risk factors for portopulmonary hypertension. Hepatology，2008，48（1）:196-203.
[7] Talwalkar JA，Swanson KL，Krowka MJ，et al. Prevalence of spontaneous portosystemic shunts in patients with portopulmonary hypertension and effect on treatment. Gastroenterology，2011，141（5）:1673-1679.
[8] Krowka MJ，Miller DP，Barst RJ，et al. Portopulmonary hypertension:a report from the US-based REVEAL Registry. Chest， 2012，141（4）:906-915.
[9] Pellicelli AM，Barbaro G，Puoti C，et al. Plasma cytokines and portopulmonary hypertension in patients with cirrhosis waiting for orthotopic liver transplantation. Angiology，2010，61（8）:802-806.
[10] Roberts KE，Fallon MB，Krowka MJ，et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med，2009，179（9）:835-842.
[11] Hadengue A，Benhayoun MK，Lebrec D，et al. Pulmonary hypertension complicating portal hypertension:prevalence and relation to splanchnic hemodynamics. Gastroenterology，1991，100（2）:520-528.
[12] Galiè N，Hoeper MM，Humbert M，et al. Guidelines for the diagnosis and treatment of pulmonary hypertension:the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology（ESC） and the European Respiratory Society（ERS），endorsed by the International Society of Heart and Lung Transplantation （ISHLT）. Eur Heart J，2009，30（20）:2493-2537.
[13] Kim WR，Krowka MJ，Plevak DJ，et al. Accuracy of Doppler echocardiograghy in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl，2000，6（4）:453-458.
[14] Colle IO，Moreau R，Godinho E，et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation:a prospective study. Hepatology，2003，37（2）:401-409.
[15] Raevens S，Colle I，Reyntjens K，et al. Echocardiography for the detection of portopulmonary hypertension in liver transplant candidates:an analysis of cutoff values. Liver Transpl，2013，19（6）:602-610.
[16] Rodriguez-Roisin R，Krowka MJ， Fallon MB，et al. Pulmonary-hepatic vascular disorders（PHD）. Eur Respir J，2004，24（5）:861-880.
[17] Porres-Aguilar M，Zuckerman MJ，Figueroa-Casas JB，et al. Portopulmonary hypertension: state of the art. Ann Hepatol，2008，7（4）:321-330.
[18] Savale L，Magnier R，Le Pavec J，et al. Efficacy，safety and pharmacokinetics of bosentan in portopulmonary hypertension. Eur Respir J，2013，41（1）:96-103.
[19] Eriksson C，Gustavsson A，Kronvall T，et al. Hepatotoxicity by bosentan in a patient with portopulmonary hypertension:a case-report and review of the literature. J Gastrointestin Liver Dis，2011，20（1）:77-80.
[20] Austin MJ，McDougall NI，Wendon JA，et al. Safety and efficacy of combined use of sildenafil，bosentan and iloprost before and after liver transplantation in serever portolulmonary hypertension. Liver Transpl，2008，14（3）:287-291.
[21] Seferian A，Simonneau G. Therapies for pulmonary arterial hypertension:where are we today，where do we go tomorrow Eur Respir Rev，2013，22（129）:217-226.
[22] Findlay JY，Harrison BA，Plevak DJ，et al. Inhaled nitric oxide reduces pulmonary artery pressures in portopulmonary hypertension. Liver Transpl Surg，1999，5（5）:381-387.
[23] Krowka MJ， Plevak DJ，Findlay JY，et al. ulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl，2000，6（4）:443-450.
[24] Bozbas SS，Eyuboglu FO，Arslan NG，et al. The prevalence and the impact of portopulmonary hypertension on postoperative course in patients undergoing liver transplantation. Transplant Proc，2009，41（7）:2860-2863.
[25] Bandara M，Gordon FD，Sarwar A，et al. Successful outcomes following living donor liver transplantation for portopulmonary hypertension. Liver Transpl，2010，16（8）:983-989.
[26] Raevens S，De Pauw M，Reyntjens K，et al. Oral vasodilator therapy in patients with moderate to severe portopulmonary hypertension as a bridge to liver transplantation. Eur J Gastroenterol Hepatol，2013，25（4）:495-502.
[27] Scouras NE，Matsusaki T，Boucek CD，et al. Portopulmonary hypertension as an indication for combined heart，lung，and liver or lung and liver transplantation:literature review and case presentation. Liver Transpl，2011，17（2）:137-143.

门脉性肺动脉高压的诊断与治疗进展

Progress in diagnosis and treatment of patients with portopulmonary hypertension

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	庄莹, 林志辉. 肝硬化并发门静脉血栓临床表现和诊断进展[J]. 实用肝脏病杂志, 2019, 22(6): 765-767.
[2]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[3]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[4]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[5]	石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.
[6]	吴海义, 陈建新. 四种诊断模型诊断乙型肝炎病毒携带者肝纤维化的效能分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 832-835.
[7]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[8]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[9]	杨才勇, 陈娜, 李奎, 江自成, 卜蓉蓉. 慢性丙型肝炎和丙型肝炎肝硬化患者外周血Treg和Th17水平变化临床意义探讨^*[J]. 实用肝脏病杂志, 2019, 22(6): 868-871.
[10]	朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 872-875.
[11]	武丹, 马向鹰. 非酒精性脂肪性肝病肝硬化患者胰岛素抵抗水平与颈动脉硬化程度和左心室功能研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 876-879.
[12]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[13]	刘李, 杨烈, 陈海洋, 何承俊, 王建宇, 陈廷昊. 肝硬化门静脉高压症并发脾动脉盗血综合征患者脾切除联合贲门周围血管离断术后门脉血流动力学的变化^*[J]. 实用肝脏病杂志, 2019, 22(6): 884-887.
[14]	何志安, 余丽萍, 赖江琼, 黄思付. ARFI评估肝硬化并发食管胃底静脉曲张患者出血和门静脉血栓的价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 888-891.
[15]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.